Welcome to our dedicated page for Encompass Health SEC filings (Ticker: EHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Encompass Health Corporation filings document the operating results, financing arrangements and governance matters of a public inpatient rehabilitation hospital company. Its Form 8-K reports furnish earnings releases, Regulation FD materials, same-store performance measures and non-GAAP metrics such as adjusted earnings per share, leverage ratio, Adjusted EBITDA and adjusted free cash flow.
Other filings record capital-structure and governance subjects, including the company's credit agreement, revolving credit facility, subsidiary guarantor arrangements, board appointments, committee assignments and director compensation practices. The definitive proxy statement addresses annual meeting proposals, executive compensation, pay-versus-performance disclosure, board structure and stockholder voting matters.
Encompass Health Corp reported an equity award to director Cain A. Hayes. On January 30, 2026, Hayes received 457 shares of Encompass Health common stock at a price of $0 per share, granted as restricted stock units under the company’s 2025 Omnibus Performance Incentive Plan. Following this award, Hayes directly beneficially owns 457 shares of Encompass Health common stock.
Encompass Health Corp filed an initial ownership report for director Cain A. Hayes. The filing states that, as of the event date of 01/30/2026, he is a director of the company and that no Encompass Health securities are beneficially owned.
Encompass Health Corp director Greg D. Carmichael reported receiving 28 shares of Encompass Health common stock on January 15, 2026, recorded at a price of $0 per share as a stock-based award. Following this transaction, he beneficially owned 18,659 shares directly.
The filing explains that this award reflects additional restricted stock units credited to non-employee directors in connection with common stock dividend payments. On January 15, 2026, Encompass Health paid a $0.19 per share dividend when the stock’s closing price was $102.80, and the 28 RSUs reported are tied to that dividend-related accrual.
Encompass Health Corp director Joan E. Herman reported an automatic equity award tied to the company’s common stock dividend. On January 15, 2026, she received 87 additional shares of Encompass Health common stock at a price of $0 per share, reflecting dividend-equivalent credits under outstanding restricted stock unit award agreements.
The filing notes Encompass Health paid a $0.19 per share dividend on its common stock on that date, when the stock’s closing price was $102.80. Following this award, Herman beneficially owned 47,839 shares of Encompass Health common stock directly.
Encompass Health Corp director reports dividend-linked RSU award
Encompass Health Corp director Leslye G. Katz filed a Form 4 reporting an automatic award of 87 restricted stock units (RSUs) of Encompass Health common stock on January 15, 2026. The RSUs were credited at a price of $0 per unit, increasing her directly held beneficial ownership to 47,839 shares.
According to the footnote, non-employee directors receive additional RSUs in connection with common stock dividend payments. On January 15, 2026, Encompass Health paid a cash dividend of $0.19 per share, and the RSU credit was calculated using the closing stock price of $102.80 on the dividend payment date.
Encompass Health Corp director Kevin J. O'Connor reported a small dividend-related equity grant. On January 15, 2026, he acquired 17 shares of Encompass Health common stock at a reported price of $0, bringing his directly held stake to 9,912 shares. According to the award terms, this reflects restricted stock units credited to non-employee directors in connection with common stock dividend payments. For this dividend, Encompass Health paid $0.19 per share, and the closing stock price on the payment date was $102.80, which was used to calculate the number of RSUs credited.
Encompass Health Corp director Nancy M. Schlichting reported an automatic award of 40 shares of Encompass Health common stock on January 15, 2026. The shares were credited at a price of $0.00 per share as restricted stock units tied to the company’s common stock dividend. The footnote explains that non-employee directors receive additional RSUs whenever dividends are paid, based on the number of existing RSUs, the per-share dividend of $0.19, and the closing price of $102.80 on the dividend payment date. Following this transaction, Schlichting beneficially owned 21,259 shares of Encompass Health common stock in direct form.
Encompass Health Corp director Terrance Williams reported a routine equity award linked to the company’s dividend. On January 15, 2026, he acquired 28 shares of Encompass Health common stock at a stated price of $0, bringing his total beneficial ownership to 15,169 shares.
According to the award agreements, additional restricted stock units are credited to each non-employee director when Encompass Health pays common stock dividends. For this dividend, the company paid $0.19 per share and the stock’s closing price was $102.80, resulting in an RSU award associated with that dividend payment.
Encompass Health Corp director Edward M. Christie III reported acquiring additional company stock on January 15, 2026. He received 9 shares of Encompass Health common stock at $0.00 per share as part of an award of restricted stock units tied to a cash dividend of $0.19 per share, based on a closing price of $102.80.
On the same date, he acquired a further 269 shares at a weighted average price of $102.82 per share through the company’s Directors Deferred Stock Investment Plan, which reinvests deferred director fees and related dividends in common stock. Following these transactions, he directly held 7,182 shares of Encompass Health common stock.
Encompass Health Corp director Christopher R. Reidy reported routine share acquisitions tied to director compensation arrangements. On January 15, 2026, he received 19 shares of Encompass Health common stock valued at $0 per share through an award of restricted stock units connected to a $0.19-per-share dividend. On the same date, he acquired an additional 346 shares at a weighted average price of $103.07 per share through the company’s Directors Deferred Stock Investment Plan, which uses deferred director fees and reinvested dividends to purchase stock in the market. Following these transactions, Reidy directly beneficially owned 15,450 shares of Encompass Health common stock.